Does the Impact of COVID‐19 on Patients With Systemic Sclerosis Change Over Time?
Open Access
- 11 December 2023
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 76 (1) , 88-97
Abstract
Objective: The outcome of patients with COVID‐19 improved over the pandemic, including patients with systemic rheumatic diseases. However, data on patients with systemic sclerosis (SSc) are lacking. This study aimed to assess the outcome of patients with both SSc and COVID‐19 over several waves.Methods: Patients with both SSc and COVID‐19 who were registered in the European Scleroderma Trials and Research group (EUSTAR) were collected between April 2020 and April 2021. Patients were assigned to waves 1, 2, or 3 depending on the date of their COVID‐19 diagnosis. Primary endpoints were death, intensive care unit stay, or ventilatory support (severe outcome). Subgroup analyses of patients who were hospitalized or died were conducted. General and SSc‐specific characteristics and treatment were compared over the waves. Descriptive statistics and multivariate logistic regression were applied.Results: A total of 333 patients were included; 57 patients (17%) had a severe outcome, and 30 patients (9%) died. Compared to wave 1, significantly fewer patients with SSc suffered from severe COVID‐19 in waves 2 and 3 (28.2% vs 9.8% and 12.7%; P < 0.001), fewer patients required hospitalization (46.7% vs 19.6% and 25.5%; P < 0.001) or ventilatory support (24.0% vs 8.7% and 10.9%; P = 0.001), and fewer patients died (15.7% vs 5.0% and 7.5%; P = 0.011). Patients were significantly younger, more often men, had less frequent arterial hypertension, and less SSc cardiac involvement over waves 1 to 3. Patients received significantly less medium to high doses of corticosteroids as they did SSc treatment.Conclusion: The outcome of patients with both SSc and COVID‐19 improved significantly over time because of intrinsic and extrinsic factors.Keywords
This publication has 24 references indexed in Scilit:
- Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registryAnnals of the Rheumatic Diseases, 2021
- Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximabAnnals of the Rheumatic Diseases, 2021
- Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort studyThe Lancet Rheumatology, 2021
- Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patientsPLOS ONE, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- An interactive web-based dashboard to track COVID-19 in real timeThe Lancet Infectious Diseases, 2020
- Mapping and predicting mortality from systemic sclerosisAnnals of the Rheumatic Diseases, 2017
- Systemic sclerosisThe Lancet, 2017
- Systemic sclerosisNature Reviews Disease Primers, 2015
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnnals of the Rheumatic Diseases, 2010